title: Association between EGFR gene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients.
abstract: Cetuximab and panitumumab are epidermal growth factor receptor (EGFR) inhibitors used in metastatic colorectal cancer (mCRC). Most patients develop a papulopustular rash that may predict tumor response to treatment. EGFR gene polymorphisms may also determine tumor response and appearance of skin rash. We hypothesized an association between EGFR gene polymorphisms, papulopustular rash and response to anticancer treatment. Four EGFR polymorphisms (-216, -191, CA-SSR, R521K) were analysed in 51 patients with mCRC receiving anti-EGFR. Severity of cutaneous rash and tumor response was measured following standard scales. We report an association between SNP-216 and tumor response (P = 0.003): no tumor progression occurred in TT genotype. Moreover, 92.3% of the responder patients developed skin rash, 62.9% of them presenting a grade ≥2 (P = 0.015). Thus, although underpowered, our preliminary data suggest that SNP-216 polymorphism of the EGFR gene could be useful in predicting tumor response and the appearance of severe skin rash might also be associated.
authors.affiliation: Department of Dermatology, Donostia University Hospital, San Sebastián, Spain.
authors.forename: Ane
authors.initials: A
authors.lastname: Jaka
authors.forename: Araika
authors.initials: A
authors.lastname: Gutiérrez-Rivera
authors.forename: Nerea
authors.initials: N
authors.lastname: Ormaechea
authors.forename: Jesus
authors.initials: J
authors.lastname: Blanco
authors.forename: Adelaida
authors.initials: A
authors.lastname: La Casta
authors.forename: Cristina
authors.initials: C
authors.lastname: Sarasqueta
authors.forename: Ander
authors.initials: A
authors.lastname: Izeta
authors.forename: Anna
authors.initials: A
authors.lastname: Tuneu
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000068818:Cetuximab / Q000009:adverse effects / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000556:secondary / Q000628:therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics; D005076:Exanthema / Q000209:etiology* / Q000235:genetics; D005260:Female; D018773:Genes, erbB-1; D006801:Humans; D008297:Male; D018895:Microsatellite Repeats; D008875:Middle Aged; D008957:Models, Genetic; D000077544:Panitumumab; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab
keywords: EGFR; EGFR polymorphisms; anti-EGFR (Cetuximab, Panitumumab); colorectal cancer; skin rash